NCT05477875View on ClinicalTrials.gov

Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control

PHASE2CompletedINTERVENTIONAL
Enrollment

35

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

January 22, 2025

Study Completion Date

January 22, 2025

Conditions
Photorefractive KeratectomyMyopiaHyperopia
Interventions
DRUG

oral cannabinoid

dronabinol

COMBINATION_PRODUCT

oral codeine/acetaminophen

10 tablets of acetaminophen-codeine combination (300-30mg) without refills.

Trial Locations (1)

32605

University of Florida Oaks Eye Center, Gainesville

All Listed Sponsors
collaborator

Consortium for Medical Marijuana Clinical Outcomes Research

OTHER

lead

University of Florida

OTHER

NCT05477875 - Cannabinoid vs Opioid for Photorefractive Keratectomy Pain Control | Biotech Hunter | Biotech Hunter